4,902 results match your criteria Plaque Psoriasis

Tacrolimus-loaded chitosan nanoparticles for enhanced skin deposition and management of plaque psoriasis.

Carbohydr Polym 2021 Sep 23;268:118238. Epub 2021 May 23.

Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt. Electronic address:

Tacrolimus is a natural macrolide that exhibits an anti-proliferative action by T-lymphocytic cells inhibition. Hence, it was tested as a potential topical treatment to improve and control psoriatic plaques. In this study, for the first time the lipophilic tacrolimus in chitosan nanoparticles was used to achieve the desired response and dermal retention of the drug using a modified ionic gelation technique. Read More

View Article and Full-Text PDF
September 2021

Calcipotriol/Betamethasone Dipropionate Aerosol Foam for Plaque Psoriasis: A Prospective, Observational, Non-Interventional, Single-Center Study of Patient Adherence and Satisfaction in Daily Use.

Dermatol Pract Concept 2021 May 20;11(3):e2021056. Epub 2021 May 20.

Department of Psoriasis, Dermatology, Hospital Universitario San Cecilio, Granada, Spain.

Background: Psoriasis is a chronic inflammatory disease that has a negative impact on patients' quality of life. Patients with mild-moderate psoriasis can be treated with topical medications, such as the combination drug calcipotriol/betamethasone dipropionate (Cal/BD).

Objectives: This study investigated the adherence of psoriasis patients to therapy with Cal/BD aerosol foam, as well as their satisfaction with the treatment's efficacy, safety, and effect on their quality of life. Read More

View Article and Full-Text PDF

Prevalence of Metabolic Syndrome and Its Parameters and Their Correlations With Psoriasis Duration, Severity, and Sleep Quality In Psoriasis Patients: A Cross-Sectional Study.

Dermatol Pract Concept 2021 May 20;11(3):e2021049. Epub 2021 May 20.

Department of Neurology, University of Health Sciences, Bakirkoy Prof. Dr. Mazhar Osman Research and Training Hospital, Istanbul, Turkey.

Background: Psoriasis is an inflammatory skin disease that may lead to comorbidities, including metabolic syndrome (MS).

Objective: We determined the prevalence of MS and its correlation with psoriasis duration, severity, and sleep quality in psoriasis patients.

Methods: A total of 112 subjects with chronic plaque psoriasis were studied. Read More

View Article and Full-Text PDF

Dimethyl fumarate titration for the systemic treatment of moderate-to-severe plaque psoriasis.

Drugs Context 2021 31;10. Epub 2021 May 31.

Dermatology Department, DissaL, Policlinico San Martino IRCCS, Genova, Italy.

Background: Dimethyl fumarate (DMF) is an oral systemic agent approved for the treatment of moderate-to-severe psoriasis vulgaris. It has a favourable tolerability profile, but it is associated with a high incidence of mild and reversible adverse events. The aim of the article is to describe a clinical experience aimed at increasing tolerability. Read More

View Article and Full-Text PDF

Successful management of treatment resistant nail psoriasis with tildrakizumab.

Australas J Dermatol 2021 Jun 11. Epub 2021 Jun 11.

Dermatology Department, The Royal Melbourne Hospital, Parkville, Victoria, Australia.

Nail psoriasis significantly impacts quality of life and is notoriously difficult to treat. Tildrakizumab, an IL-23 inhibitor, has shown significant clinical improvement in the treatment of moderate-to-severe chronic plaque psoriasis. We report 2 cases of treatment resistant nail psoriasis which showed marked improvement with the use of off-label tildrakizumab. Read More

View Article and Full-Text PDF

Use of brodalumab for the treatment of chronic plaque psoriasis: a one-year real-life study in the Lazio region, Italy.

Expert Opin Biol Ther 2021 Jun 11. Epub 2021 Jun 11.

Dipartimento Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, Dermatologia, Rome, Italy.

Background: Information is limited from real-life studies evaluating the efficacy and safety of brodalumab.

Research Design And Methods: In this real-life study, we retrospectively examined a database of 90 patients with moderate-to-severe psoriasis treated with brodalumab (210 mg, s.c. Read More

View Article and Full-Text PDF

Single-nucleotide polymorphism and haplotype analysis of macrophage migration inhibitory factor gene and its correlation with serum macrophage migration inhibitory factor levels in North Indian psoriatic patients with moderate disease severity: A cross-sectional study.

Indian J Dermatol Venereol Leprol 2021 May 8:1-7. Epub 2021 May 8.

Department of Dermatology, Venereology and Leprosy, Postgraduate Institute of Medical Education and Research, Chandigarh, India.

Background: Psoriasis is associated with significant morbidity and impaired quality of life. Identification of the host genes that influence disease susceptibility and can potentially guide future, targeted therapy is the need of the hour.

Aims: The aim of the study was to investigate the associations of macrophage migration inhibitory factor (MIF) gene polymorphisms, that is, a 5-8-CATT tetra nucleotide repeats at -794 (-794*CATT5-8) and a single-nucleotide polymorphism at -173 (-173*G/C) with the risk of chronic plaque psoriasis and to observe the correlation, if any, of disease determinants with genetic functional variants and circulating MIF levels. Read More

View Article and Full-Text PDF

Patterns of Comorbidities in Psoriasis Patients: A Cross-Sectional Study.

Cureus 2021 May 8;13(5):e14907. Epub 2021 May 8.

Dermatology, King Abdulaziz Medical City, Jeddah, SAU.

Background: Psoriasis is a chronic, inflammatory, and immune-mediated dermatological disease of unknown etiology with predominant involvement of the skin, nails, and joints. This study aimed to assess comorbidities patterns in psoriasis patients.

Methods: This is a cross-sectional study conducted at King Abdulaziz Medical City (KAMC) in Jeddah, Saudi Arabia. Read More

View Article and Full-Text PDF

Dose escalation and associated costs in biologic treatment of psoriasis based on real-world data.

J Med Econ 2021 Jan-Dec;24(1):782-791

Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Objectives: This study documents real-world patterns and additional costs of above-label (≥10% above the recommended maintenance dose) use of biologics in patients with plaque psoriasis.

Materials And Methods: This was a descriptive, retrospective cohort analysis using the IBM MarketScan Commercial and Medicare Supplemental Databases. Adult patients diagnosed with plaque psoriasis initiating treatment with etanercept, adalimumab, ixekizumab, or secukinumab between 1 January 2015 and 30 November 2019 (index) were eligible. Read More

View Article and Full-Text PDF

Ixekizumab for the treatment of pediatric patients with moderate to severe plaque psoriasis.

Expert Opin Biol Ther 2021 Jun 9:1-8. Epub 2021 Jun 9.

Modern Research Associates, Dallas, TX, USA.

: Ixekizumab (IXE), a high affinity humanized monoclonal antibody that selectively targets interleukin-17A, is approved in the United States (US) and the European Union (EU) for pediatric patients with moderate to severe plaque psoriasis. This review summarizes ixekizumab use in the phase 3, randomized, double-blind, placebo-controlled study in pediatric patients with moderate to severe plaque psoriasis and provides some clinical pearls we have learned after using the drug in the pediatric population for the past 3 years.: Review of IXORA-PEDS trial data, general literature review pertaining to the systemic treatment of pediatric psoriasis as well as our clinical experience with IXE: IXE is the only IL17 antagonist for pediatric psoriasis and is a welcome addition to our armamentarium. Read More

View Article and Full-Text PDF

Fixed-Combination Halobetasol Propionate and Tazarotene in the Treatment of Psoriasis: Narrative Review of Mechanisms of Action and Therapeutic Benefits.

Dermatol Ther (Heidelb) 2021 Jun 9. Epub 2021 Jun 9.

Ortho Dermatologics, Bausch Health US, LLC (an Affiliate of Bausch Health Companies Inc.), Bridgewater, NJ, USA.

Psoriasis is a lifelong disease associated with cycles of remission and relapse. Topical treatments are the front line of psoriasis therapy for most patients and have antiproliferative, anti-inflammatory, and immunosuppressive mechanisms of action. Novel fixed-dose combinations of topical therapeutic agents are becoming increasingly available, leveraging multiple mechanisms of action to improve safety and efficacy with formulations that are easier to use and may allow for the use of lower doses of active ingredients. Read More

View Article and Full-Text PDF

Treatment of moderate-to-severe plaque psoriasis with tildrakizumab in the real-life setting.

Drugs Context 2021 21;10. Epub 2021 May 21.

Division of Dermatology, Department of Health and Science (DissaL), Policlinico San Martino Hospital, IRCCS, Genova, Italy.

Background: Tildrakizumab is a high-affinity, humanized IgG1κ monoclonal antibody targeting the p19 subunit of IL-23, which is a key regulatory cytokine in psoriasis. Based on evidence from clinical trials, tildrakizumab is approved for the treatment of moderate-to-severe plaque psoriasis in patients eligible for systemic therapy.

Methods: We report our clinical experience with 26 patients followed up to 24 weeks. Read More

View Article and Full-Text PDF

Psoriatic Alopecia in a Patient With Crohn Disease: An Uncommon Manifestation of Tumor Necrosis Factor α Inhibitors.

Cutis 2021 Apr;107(4):E48-E55

University of Puerto Rico School of Medicine, San Juan. Drs. Carrasquillo, Barrera-Llaurador, Colón-Fontanez, and Martín-García are from the Department of Dermatology, and Dr. Pabón-Cartagena is from the Transitional Year Program.

Tumor necrosis factor α (TNF-α) inhibitors are used to treat multiple inflammatory diseases including rheumatoid arthritis, inflammatory bowel disease, and psoriasis, among others. This family of medications can cause various side effects, some as common as injection-site reactions and others as rare as the paradoxical induction of psoriasiform skin lesions. Alopecic plaques recently have been described as an uncommon adverse effect of the TNF-α inhibitors adalimumab and infliximab. Read More

View Article and Full-Text PDF

Apremilast Uses and Relevance to the Military.

Cutis 2021 Apr;107(4):216-220

Department of Dermatology, Naval Medical Center San Diego, California.

Apremilast is a small-molecule biologic approved by the US Food and Drug Administration (FDA) for use in plaque psoriasis, psoriatic arthritis, and Behçet disease. Although apremilast is seemingly a less favorable choice for treating psoriasis in the era of injectable biologics, the drug is an important option for patients in the military. In this article, we review on-label indications and off-label uses for apremilast; highlight the importance of apremilast for managing psoriasis in the military population; and propose other patient populations in whom the use of apremilast is favorable. Read More

View Article and Full-Text PDF

Risankizumab for the Treatment of Moderate-to-Severe Psoriasis: Real-Life Multicenter Experience from the Czech Republic.

Dermatol Ther (Heidelb) 2021 Jun 5. Epub 2021 Jun 5.

Department of Dermatovenereology, First Faculty of Medicine and General University Hospital, Charles University, Prague, Czech Republic.

Introduction: Risankizumab has been approved for the treatment of moderate-to-severe plaque psoriasis; however, real-life data are limited. Our objectives were to evaluate the effectiveness and safety of risankizumab and its impact on the quality of life of patients with psoriasis in a real-world setting.

Methods: We retrospectively analyzed 154 patients from 18 centers in the Czech Republic who had undergone biologic therapy with risankizumab for moderate-to-severe plaque psoriasis. Read More

View Article and Full-Text PDF

Inhibition of dipeptidyl-peptidase 4 induces upregulation of the late cornified envelope cluster in keratinocytes.

Arch Dermatol Res 2021 Jun 5. Epub 2021 Jun 5.

Division of Dermatology, Department of Otorhinolaryngology, Rush University Medical Center, 707 S Wood St. Suite 220, Chicago, IL, 60612, USA.

Dipeptidyl-peptidase 4 (DPP4) is a multifunctional type II transmembrane glycoprotein that is expressed on various cell surfaces. While DPP4 inhibitors have a therapeutic role in the treatment of diabetes mellitus, they are an independent risk factor in the development of bullous pemphigoid. Contrarily, there are reports of improvement in psoriasis with DPP4 inhibition. Read More

View Article and Full-Text PDF

Dose Adjustment of Biologic Treatments for Moderate-to-Severe Plaque Psoriasis in the Real World: A Systematic Review.

Dermatol Ther (Heidelb) 2021 Jun 3. Epub 2021 Jun 3.

LEO Pharma A/S, Ballerup, Denmark.

Introduction: Dose escalation and reduction of biologic treatments are frequent in clinical practice. The aim of this systematic review is to summarise evidence on dose adjustment of biologic treatments for moderate-to-severe plaque psoriasis in the real-world.

Methods: A systematic review of real-world evidence on dose adjustment of biologics for plaque psoriasis was performed. Read More

View Article and Full-Text PDF

Skin and soft tissue infections in biological therapy for psoriasis-A case report and systematic review of the literature.

Int J Dermatol 2021 Jun 3. Epub 2021 Jun 3.

Dermatology and Venereology Department, Emek Medical Center, Afula, Israel.

Background: Biological therapies are widely used for moderate to severe chronic plaque psoriasis owing to their high efficacy and safety profile. However, skin and soft tissue infections (SSTIs) have been reported in association with biological treatment in psoriasis.

Methods: We report a case of necrotizing fasciitis in an 18-year-old psoriasis patient with a history of severe combined immunodeficiency treated with secukinumab and conducted a systematic literature review of SSTIs associated with biological therapy for psoriasis. Read More

View Article and Full-Text PDF

Bimekizumab for Moderate-to-Severe Plaque Psoriasis.

Skin Therapy Lett 2021 May;26(3):1-4

Dermatrials Research Inc. & Venderm Innovations in Psoriasis, Hamilton, ON, Canada.

Psoriasis is an immune-mediated inflammatory skin disease that affects about 2% of the population and is associated with many comorbidities. Recent advances have demonstrated interleukin (IL)-17 signaling plays a crucial role in the pathogenesis of psoriasis. Bimekizumab is a novel monoclonal antibody treatment for psoriasis that uses a single binding site to inhibit IL-17A and IL-17F. Read More

View Article and Full-Text PDF

Seeing the Treatment of Psoriasis in a New Light: A Novel Medical Device Utilizing Localized Coal Tar and Narrowband UVB for Targeted Treatment of Plaque Psoriasis.

J Drugs Dermatol 2021 Jun;20(6):701-702

Given the high costs of systemic psoriasis therapies, studies have also shown that phototherapy achieves significant cost savings by replacing or delaying drug-based systemic treatment in patients with moderate to severe disease. However, this modality is often underutilized mainly due to the lack of phototherapy treatment centers across the country. Home phototherapy was designed to fill this treatment gap and allow patients to be treated with phototherapy despite living in areas that may not have a formal treatment facility. Read More

View Article and Full-Text PDF

Prevalence of Hashimoto's thyroiditis in psoriasis patients.

Rev Assoc Med Bras (1992) 2021 May 31. Epub 2021 May 31.

Hospital Evangélico Mackenzie - Curitiba (PR), Brasil.

Objective: To study the prevalence of Hashimoto's Thyroiditis in a sample of psoriasis patients.

Methods: Cross-sectional observational study of 120 individuals (60 with psoriasis and 60 control subjects) paired by gender and age for thyroid function (thyroid stimulating hormone, free T4), antithyroperoxidase and antithyroglobulin tests and physical examination. Psoriasis Area and Severity Index and Nail Psoriasis Severity Index were evaluated simultaneously. Read More

View Article and Full-Text PDF

Pustular Psoriasis and Associated Musculoskeletal Disorders.

J Rheumatol Suppl 2021 Jun;97:34-38

P.S. Helliwell, MD, PhD, Professor of Clinical Rheumatology, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Harehills Lane, Leeds, and NIHR Leeds Biomedical Research Centre, Leeds, UK.

Pustular psoriasis (PsO) is an uncommon variant of PsO that may present in a generalized or localized fashion with or without musculoskeletal or systemic inflammatory involvement.Generalized pustular PsO (GPP) presents as a widespread acute or subacute pustular eruption that may be familial and is often associated with severe flares and systemic inflammation. The palmoplantar pustulosis variant is localized to palms and soles, whereas acrodermatitis continua of Hallopeau is localized to the nail apparatus. Read More

View Article and Full-Text PDF

Milk Proteins-Their Biological Activities and Use in Cosmetics and Dermatology.

Molecules 2021 May 28;26(11). Epub 2021 May 28.

Department of Cosmetic Raw Material Chemistry, Faculty of Pharmacy, Medical University of Lodz, Muszyńskiego 1, 90-151 Łódź, Poland.

Milk and colostrum have high biological potential, and due to their natural origin and non-toxicity, they have many uses in cosmetics and dermatology. Research is ongoing on their potential application in other fields of medicine, but there are still few results; most of the published ones are included in this review. These natural products are especially rich in proteins, such as casein, β-lactoglobulin, α-lactalbumin, lactoferrin, immunoglobulins, lactoperoxidase, lysozyme, and growth factors, and possess various antibacterial, antifungal, antiviral, anticancer, antioxidant, immunomodulatory properties, etc. Read More

View Article and Full-Text PDF

Pathophysiology of moderate to severe plaque psoriasis: anti-IL-17 towards disease modification.

S Magina P Filipe

Drugs Today (Barc) 2021 May;57(5):347-357

Serviço de Dermatologia e Venereologia, Hospital de Santa Maria, Centro Hospitalar e Universitário Lisboa Norte, Lisboa, Portugal.

Psoriasis is a chronic inflammatory disease that can be triggered by injury, trauma, infection and medications. Genetic and immunologic studies have highlighted the importance of the interleukin (IL)-23/T-helper 17 (Th17) pathway in systemic psoriasis pathogenesis. Main IL-23 is an upstream regulatory cytokine with direct effects on epidermal keratinocytes and other resident skin cells while IL-17, a downstream molecule, can activate inflammatory responses in different cells across a diversity of organs. Read More

View Article and Full-Text PDF

Efficacy and Safety of Netakimab, A Novel Anti-IL-17 Monoclonal Antibody, in Patients with Moderate to Severe Plaque Psoriasis. Results of A 54-Week Randomized Double-Blind Placebo-Controlled PLANETA Clinical Trial.

Dermatol Ther (Heidelb) 2021 May 31. Epub 2021 May 31.

JSC BIOCAD, St-Petersburg, Russia.

Introduction: Netakimab (NTK), an original humanized anti-interleukin-17 monoclonal antibody, showed therapeutic efficacy in moderate-to-severe plaque psoriasis in a phase 2 clinical study. Herein we report the results of 54 weeks of a phase 3 PLANETA trial aimed to evaluate the efficacy and safety of two NTK regimens vs. placebo. Read More

View Article and Full-Text PDF

Low incidence rate of respiratory and viral infections over 5 years of treatment with tildrakizumab in patients with moderate-to-severe psoriasis: pooled analysis from reSURFACE 1 and reSURFACE 2 phase 3 trials.

J Eur Acad Dermatol Venereol 2021 May 31. Epub 2021 May 31.

Department of Medicine, Section of Dermatology and Venereology, University of Verona, Verona, Italy.

In the context of the current coronavirus disease 2019 (COVID-19) pandemic, there is no direct evidence to support any preferred biologic therapy for psoriasis. However, known safety profile of different classes of biologic therapies as well as individual risk factors for infections must be considered. Here, we report incidence rates of respiratory or viral infections through 5 years among patients with moderate-to-severe plaque psoriasis who were treated with the interleukin (IL)-23p19 inhibitor tildrakizumab from reSURFACE 1 and reSURFACE 2 phase III trials. Read More

View Article and Full-Text PDF

Bulky Condyloma Acuminata following Ustekinumab Treatment for Plaque Psoriasis: A Case Report.

Case Rep Dermatol 2021 Jan-Apr;13(1):244-247. Epub 2021 Apr 21.

Section of Dermatology, DISSAL, San Martino-IST Polyclinic Hospital, University of Genoa, Genoa, Italy.

Ustekinumab is a fully human monoclonal antibody targeting the pro-inflammatory cytokines interleukin (IL)-12 and IL-23 approved for the treatment of psoriasis and psoriatic arthritis. We report a case of a patient treated for chronic plaque psoriasis with ustekinumab who developed bulky condyloma acuminata shortly after initiating the treatment. Although ustekinumab has already been described in literature associated with other forms of human papilloma virus skin infections, this is the first case to our knowledge in which ustekinumab is associated with genital warts. Read More

View Article and Full-Text PDF

Characterization and Outcomes in Patients Treated With Apremilast in Routine Clinical Practice in Spain: Results From the APPRECIATE Study.

Actas Dermosifiliogr 2021 May 27. Epub 2021 May 27.

Vithas Xanit Iinternational Hospital, Benalmádena, Málaga, España.

Background And Objectives: More knowledge about the use of apremilast in real-world settings is needed. The APPRECIATE study (NCT02740218) was designed to describe the characteristics of patients with psoriasis treated with apremilast in routine clinical practice in Spain, evaluate patients' and dermatologists' expectations, and analyze outcomes.

Methods: Retrospective, observational, cross-sectional, multicenter study of patients with chronic plaque psoriasis seen 6 months (plus or minus 1 month) after starting treatment with apremilast. Read More

View Article and Full-Text PDF

Real world experience with risankizumab in patients with plaque psoriasis: A retrospective study.

J Eur Acad Dermatol Venereol 2021 May 29. Epub 2021 May 29.

SKiN Centre for Dermatology, 775 Monaghan Rd., Peterborough, ON, K9J 5K2, Canada.

Recently, the phase 3 trials IMMvent and IMMhance reported that 84% of patients treated with risankizumab for moderate-to-severe plaque psoriasis achieved a physician global assessment (PGA) score of 0 or 1 after 16 weeks [1,2]. However, there is currently limited evidence for its use in real-world clinical practice [3-5]. A retrospective chart review was conducted at a dermatology clinic with two sites in Ontario, Canada, from June 2019 to January 2020 to analyze the safety and efficacy of risankizumab. Read More

View Article and Full-Text PDF

Dynamic Visual Representation of Clinical Efficacy of Ixekizumab in Psoriasis.

Dermatol Ther (Heidelb) 2021 May 29. Epub 2021 May 29.

Central Dermatology, St. Louis, MO, USA.

Introduction: Ixekizumab, a high-affinity monoclonal antibody that selectively targets interleukin-17A, is an approved treatment for plaque psoriasis. This study aimed to use animated visualizations as a tool to simplify complex data from ixekizumab clinical trials.

Methods: Animated visualizations were developed to show outcomes from ixekizumab clinical trials and a Bayesian network meta-analysis of 11 approved biologics. Read More

View Article and Full-Text PDF